Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB 0017

Next Previous
X
Search
Drug Profile

HB 0017

Alternative Names: HB-0017; HB-017; Recombinant humanized IgG1 monoclonal antibody - Huabo Biopharm

Latest Information Update: 25 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Huabo Biopharm
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II Ankylosing spondylitis; Psoriatic arthritis

Most Recent Events

  • 19 Sep 2024 Huabo Biopharm plans a phase II trial for Plaque psoriasis in China (Parenteral, Injection) in September 2024 (NCT06592274)
  • 01 Mar 2024 Phase-III clinical trials in Plaque psoriasis (In adults, In the elderly) in China (SC) (NCT06477237)
  • 04 Jan 2024 Huabo Biopharm completes a phase II trial in Plaque psoriasis in China (SC) (NCT05531682)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top